

Patient blood management in colorectal cancer patients: a survey among Dutch gastroenterologists, surgeons and anesthesiologists

M.J. (Michael Jordi) Wilson, MD^{1,2§}, A.W.M.M. (Ankie) Koopman-van Gemert³, MD PhD, J.J. (Joris) Harlaar, MD PhD^{4,5}, J. (Johannes) Jeekel, MD PhD⁶, J.J. (Jaap Jan) Zwaginga, MD PhD^{7,8*}, M. (Martin) Schipperus, MD PhD^{1,9*}

* contributed equally

¹TRIP Hemovigilance and Biovigilance Office, Leiden, the Netherlands

²Erasmus University Medical Center Rotterdam, Department of Surgery, the Netherlands

³Albert Schweitzer Hospital, Department of Anesthesiology, Dordrecht, the Netherlands

⁴VU Medical Center Amsterdam, Department of Surgery, the Netherlands

⁵Westfriesgasthuis Hoorn, Department of Surgery, the Netherlands

⁶Erasmus University Medical Center Rotterdam, Department of Neuroscience, the Netherlands

⁷Center for Clinical Transfusion Research, Sanquin Research, Leiden, the Netherlands

⁸Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, the Netherlands

⁹Haga Teaching Hospital the Hague, Department of Hematology, the Netherlands

§ Corresponding author: Michael Wilson, MD

Erasmus MC, University Medical Center, Rotterdam

Department of Surgery, Room Z-838, PO Box 2040

3000 CA Rotterdam, the Netherlands.

E-mail address: m.wilson@erasmusmc.nl

M.J. Wilson, A.W.M.M. Koopman-van Gemert, J. Harlaar, J. Jeekel, J.J. Zwaginga, and M. Schipperus do not have any conflict of interest or financial involvement with this manuscript

Abstract

Introduction: There is an increasing awareness to integrate patient blood management (PBM) within routine surgical care in order to improve patient outcome. Although often standard in orthopedic and cardiac surgery, limited information about the use and implementation of PBM in colorectal cancer surgery is available. This is curious, as preoperative anemia, associated with increased morbidity and mortality, is highly prevalent in colorectal cancer patients. The present study therefore aimed to assess the current preoperative blood management strategies in the Netherlands, and to identify preferences of different physicians in the treatment of preoperative anemia in this particular patient group.

Methods: An online electronic survey was developed and sent to all surgeons of the Dutch Taskforce Coloproctology (177 in total). In addition, for each hospital in which surgery for colorectal cancer surgery is performed (75 in total), the survey was sent to one gastroenterologist and one anesthesiologist. Analyses of survey data were performed using descriptive statistics

Results: A total of 192 physicians responded to the survey (overall response rate 58.7%). In 73 hospitals (97.3%) the survey was conducted by at least one physician, and in more detail, in 21 hospitals (28.0%) the survey was conducted by a surgeon, an anesthesiologist and a gastroenterologist. Regarding the management of a mild to moderate preoperative anemia, no clear policy was reported in half of the hospitals (49.3%). Treatment of a mild to moderate preoperative anemia was initiated by the gastroenterologist, 14.7%; surgeon, 20.0%; colon care nurse, 5.3%; hematologist, 2.7%; anesthesiologist, 2.7%. In 38.7% of the hospitals, iron parameters were measured during screening for colorectal cancer. In addition, in only 13.3% of the hospitals, iron parameters were measured by the anesthesiologist during preoperative assessment. The most important objective for the treatment of anemia was 'the prevention of blood transfusions because of their association with impaired long-term tumor prognosis'. Furthermore, the severity of anemia was considered as the most important factor to treat anemia (98% of all respondents).

Conclusion: The present study shows a distinct variability in preoperative blood management practices in colorectal cancer care. Strikingly, this variability which was not only seen among, but also within Dutch hospitals, was demonstrated by variable responses from gastroenterologists, surgeons and anesthesiologists from the same institution. As a result, the present study clearly demonstrates the lack of consensus on PBM among gastroenterologists, surgeons and anesthesiologists, resulting in a suboptimal preoperative blood management strategy.

Introduction

Preoperative anemia in colorectal cancer patients is associated with an increased risk of short-term mortality and morbidity, and a decrease in long-term tumor survival.^{1,2} Iron deficiency is the principal cause of preoperative anemia and is reported in almost 50% of preoperative colorectal cancer patients.^{3,4} Transfusion, in earlier days the default therapy to correct this anemia, however, is also known to be associated with increased morbidity and mortality, as already demonstrated by Busch et al. in 1993.⁵⁻⁹ This has resulted in alternative approaches to treat preoperative anemia, which are collectively known as patient blood management (PBM).

PBM refers to 'the timely application of evidence based medical and surgical concepts designed to maintain hemoglobin concentration, optimize hemostasis and minimize blood loss in an effort to improve patient outcome'. It has been developed to promote strategies to reduce or avoid the need of blood transfusion, and therefore questions blood transfusion as the primary treatment strategy of anemia. PBM is a continuous process, initiated early in the preoperative period and continued intra- and postoperatively. Importantly, and by definition, PBM requires a multimodal and multidisciplinary strategy, and should at least involve surgeons, anesthesiologists, gastroenterologists, hematologists and nurses.¹⁰

The increasing awareness to integrate PBM within routine surgical care resulted in numerous ongoing trials studying the optimal blood management strategy in all types of surgery.¹¹⁻¹³ To date, studies on the use and implementation of these PBM strategies are mostly limited to orthopedic and cardiac surgery.^{10, 14} Despite the high prevalence of preoperative anemia, associated with increased morbidity and mortality, limited information about the use and implementation of PBM strategies in colorectal cancer care is available. A review by Munoz et al. represents a clear exception to this.¹⁵ In this review, the prevalence and consequences of anemia are discussed and a pragmatic approach to the treatment of perioperative anemia in colorectal cancer patients is presented.

With the present study, we focused on the preoperative assessment and treatment of anemia in colorectal cancer patients and aimed to 1) assess the current preoperative blood management strategies in the Netherlands, 2) identify preferences of different physicians (surgeons,

anesthesiologists and gastroenterologists) in the treatment of preoperative anemia, and 3) evaluate physicians' general knowledge of blood management issues.

Methods

Study design

To accomplish our objectives, an online electronic survey was developed. The survey included three topics: 1) questions on the current preoperative blood management practice in colorectal cancer patients (measurement of iron parameters and treatment of preoperative anemia), 2) questions on physicians' preferences in treatment of preoperative anemia (best treatment of preoperative anemia and the goal of treatment) and 3) questions to test physicians' knowledge of blood management issues. The survey questions were made by the research fellow (MJW) and two hematologists (MS and JJZ), and were subsequently tested at two sites (Department of Surgery Reinier de Graaf Hospital, and Department of Anesthesiology Albert Schweitzer Hospital). The eventual revised questionnaire was sent by e-mail to the eligible participants. The online survey tool *SurveyMonkey* was used to conduct the survey.

Study population

After obtaining the mailing list, the survey was first sent to all surgeons of the Dutch Taskforce ColoProctology (*Werkgroep Coloproctologie*) in May 2017. Subsequent e-mail reminders were sent out in July and September 2017. In addition, for each hospital in which surgery for colorectal cancer is performed (75 in total), the survey was sent to one gastroenterologist and one anesthesiologist, all involved in colorectal cancer care and usually the head of department. For this purpose, the survey was slightly modified to suit the clinical situation of the gastroenterologist and anesthesiologist. The first invitation was sent in June 2017 and subsequent e-mail reminders were sent out in July and September 2017. The participation period closed in October 2017.

Removal of undeliverable e-mails from the mailing list, as well as retired or relocated surgeons resulted in an adjusted study population of 177 surgeons. In addition, the study population included 75 gastroenterologists and 75 anesthesiologists. As a result, the total targeted study population was 327 physicians.

Statistics

Survey data were extracted into an Excel database. Statistical analyses were performed using SPSS (Version 21) and GraphPad Prism (Version 5). Analyses were performed using descriptive statistics.

Results

Participation

As shown in table 1, a total of 192 physicians responded to the survey (response rate 58.7%), including 95 surgeons, 48 anesthesiologists and 49 gastroenterologists. Of 192 respondents, 158 (82.2%) completed the survey, including 79 surgeons, 38 anesthesiologists and 41 gastroenterologists. In total, in 73 of 75 hospitals (97.3%) one or more physicians responded to the survey. In 21 of 75 hospitals (28.0%) the survey was conducted by a surgeon, an anesthesiologist, and a gastroenterologist.

Preoperative blood management practice

Regarding the use of red blood cell transfusions and the treatment of severe anemia, respondents from all hospitals indicated the perioperative use of a restrictive blood transfusion policy. According to the adapted 4-5-6 mmol/L hemoglobin transfusion trigger rule (Dutch transfusion guideline), the severity of anemia and the patient-specific cardiopulmonary compensation capacity was acknowledged.¹⁶

To determine the current preoperative blood management practice per hospital, all respondents were first asked to indicate the primarily responsible specialist (gastroenterologist, surgeon, hematologist, anesthesiologist, unknown or none) for the management of mild to moderate preoperative anemia in colorectal cancer patients. Strikingly, in 33 of 44 hospitals with multiple respondents (minimum of two physicians per hospital), these responses differed and were contradictory, and needed reclassification:

1. when per hospital multiple and different responses were given to the question who is primarily responsible for the treatment of mild to moderate anemia, the current preoperative blood management practice in the hospital was categorized as unclear/ambiguous.

2. when per hospital multiple and different answers were given to the question whether iron

parameters are measured during screening for colorectal cancer, the answer of the gastroenterologist was determinant.

In twelve hospitals, an ongoing randomized clinical trial (FIT trial) during the survey period studied the efficacy of preoperative intravenous iron supplementation in comparison with preoperative oral supplementation in anemic patients with colorectal cancer.¹¹ For these twelve hospitals, the content of the study protocol of the randomized trial was reflected in all answers regarding preoperative blood management practice.

As shown in table 2, iron parameters (iron, ferritin, transferrin, or transferrin saturation) were indicated to be measured during screening for colorectal cancer in 38.7% of all hospitals. Of these 29 hospitals, complete iron status (iron, ferritin, transferrin, and transferrin saturation) was indicated to be measured in four hospitals. In a total of 35 hospitals (46.7%), iron parameters were not measured during screening. In addition to the measurement of iron parameters during screening for colorectal cancer, in ten hospitals (13.3%) iron parameters were measured by the anesthesiologist at preoperative assessment, as compared to 37 hospitals (49.3%) in which iron parameters were not measured at preoperative assessment. In ten hospitals (13.3%), it was indicated that anemia observed at preoperative assessment, regardless of possible previous treatment by gastroenterologist or surgeon, was treated by the anesthesiologist, as compared to 34 hospitals (45.3%) in which this was not the case.

Regarding the treatment of preoperative anemia, respondents from nineteen hospitals (25.3%), including the twelve hospitals participating in the ongoing FIT trial, indicated that the surgeons or colon care nurses were primarily responsible (table 2). In eleven hospitals (14.7%) the gastroenterologist was the first responsible to treat a mild to moderate preoperative anemia. In two hospitals each (2.7%), hematologists and anesthesiologists were indicated as primarily responsible for treatment, while in one hospital (1.3%) it was indicated that a mild to moderate preoperative anemia was not treated. In only four hospitals, the treatment of preoperative anemia was reported to be part of a protocol, with the aim of optimizing the preoperative condition of a patient. In half of the hospitals (49.3%), no clear policy regarding the treatment of preoperative anemia was reported. In 44 hospitals

multiple responses (minimum of two physicians per hospital) to the question regarding the treatment of preoperative anemia were given, and in 33 hospitals (75.0%) these responses differed and were contradictory.

Objectives for treatment of preoperative anemia

All respondents were asked to prioritize their objectives for treatment of preoperative anemia. Results are shown in figure 1. Pooled responses demonstrated that, 'prevention of blood transfusion, because of its association with impaired long-term tumor prognosis' was ranked first, followed by 'prevention of blood transfusion, because of its short-term side effects', 'prevention of preoperative anemia, because of its association with impaired long-term tumor prognosis', 'prevention of blood transfusion, because of its high expenses', and 'optimization of preoperative hemoglobin level for enhanced hemostasis'. This order of preference was similar for the different specialisms.

Decision-making in treatment preoperative anemia

Table 3 provides percentages of respondents considering different variables in their decision to treat preoperative anemia. Only respondents who had indicated to treat preoperative anemia themselves were asked this question. Overall, 'age of patient' was considered by 63.3% of all respondents, 'presence iron deficiency' by 75.5%, 'presence clinical symptoms of anemia' by 85.7%, 'presence of comorbidities' by 83.7%, and 'severity of anemia' by 98.0%.

In case respondents indicated that their decision to treat anemia is dependent on the presence of iron deficiency, they were asked if the iron formulation (oral or intravenous) would depend on the type of iron deficiency (absolute versus functional iron deficiency), and if so, what treatment was chosen for an absolute and a functional iron deficiency anemia. Absolute iron deficiency is characterized by depleted iron stores (defined by decreased transferrin saturation and increased transferrin), while functional iron deficiency is caused by impaired iron homeostasis and is, due to increased hepcidin production, characterized by reduced iron uptake and iron mobilization from the reticulo-endothelial system (defined by decreased transferrin saturation and increased ferritin). For a small minority of respondents (44.4%) the type of iron deficiency made a difference for their treatment. In case of an absolute iron deficiency anemia, intravenous iron was the first choice of treatment for 71.4% of these

respondents (versus 28.6% oral iron). In case of a functional iron deficiency, the choice of treatment was equally divided (50% oral iron versus 50% intravenous iron).

Contraindications to intravenous iron therapy

Figure 2 provides the percentages of respondents identifying different variables as an absolute contraindication to intravenous iron therapy. Overall, contraindications to intravenous iron therapy included 'anemia not caused by iron deficiency' for 65.8% of all respondents, 'iron overload' for 79.7%, 'hypersensitivity for intravenous iron' for 86.1%, and 'bacteremia' for 15.2%. 'Renal failure' was indicated as an absolute contraindication by 15.2% of all respondents. Surgeons, gastroenterologists and anesthesiologists (78.5%, 92.1% and 95.1%, respectively) most frequently identified hypersensitivity for intravenous iron as absolute contraindication. Gastroenterologists and anesthesiologists (4.9% and 13.2%, respectively) least frequently indicated renal failure as absolute contraindication, while surgeons least frequently indicated bacteremia in this regard (7.6%).

International guidelines on the long-term effects of iron therapy

Overall, 8.9% of the respondents indicated to believe that the long-term oncological effects of intravenous iron therapy are known and already incorporated in the international guidelines on the treatment of anemia in cancer patients. 5.7% of the respondents indicated to regard intravenous iron as safe, while in contrast 3.2% of respondents believed intravenous iron therapy to be associated with impaired long-term tumor prognosis. 22.2% of the respondents indicated that the long-term oncological effects of intravenous iron therapy are not studied and therefore not included in the international guidelines. A vast majority (69%) indicated to be ignorant on this subject.

Discussion

The results of our national survey show a distinct variability in preoperative blood management practices in colorectal cancer patients. Strikingly, this variability is not only found among hospitals, but also within hospitals, demonstrated by variable responses from gastroenterologists, surgeons and anesthesiologists from the same institution. As a result, the present study clearly demonstrates the lack of consensus on PBM among gastroenterologists, surgeons and anesthesiologists, resulting in a suboptimal preoperative blood management strategy.

Extensive research on barriers limiting the translation of PBM into clinical practice has led to simplified international recommendations for the implementation of PBM¹⁷⁻²¹. One of these recommendations is that each hospital should appoint a key leader for the PBM project management, who should have a central role in charge of communication, education, and documentation. This should contribute to a more clear division in responsibilities among treating physicians. Our study clearly demonstrates that this is not the case for the vast majority of Dutch hospitals. Most gastroenterologists, surgeons and anesthesiologists referred to different persons they held primarily responsible for the treatment of a mild to moderate preoperative anemia in colorectal cancer patients. In the few hospitals practicing preoperative blood management according to protocol, the primarily responsible persons were clear for all respondents.

A second simplified recommendation is derived from the fact that effective correction of anemia will depend on the underlying disorder, and states that optimal PBM should involve screening for the underlying cause, preferably at the earliest opportunity to allow optimal correction. With respect to this recommendation, our study again showed a high variation to which extent anemia and underlying causes were investigated and identified. In only 38.7% of hospitals, iron parameters, essential for identifying type of anemia, were indicated to be measured during screening for colorectal cancer (by gastroenterologist or surgeon). In addition, in only 13.3% of hospitals, iron parameters were measured by the anesthesiologist during preoperative assessment. Most strikingly, anemia is, regardless of previous treatment by surgeon or gastroenterologists, treated by the anesthesiologist in only a quarter of the hospitals. These results clearly indicate that the majority of the Dutch hospitals are failing in the assessment and treatment of preoperative anemia.

A third recommendation is that both physicians and nurses need to be trained in PBM clinical protocols and transfusion algorithms. According to our results, much progress could be made by improving the knowledge of physicians' on these subjects. For example, in case of a functional iron deficiency, the choice of treatment was equally divided between oral and intravenous iron. This is a striking and counter-intuitive result, as oral iron is known to be nearly inefficacious in patients with a functional iron deficiency. In addition, the results of the acknowledgement of contraindications to intravenous iron emphasize the knowledge gap of the responding physicians. Renal failure, the

commonest indication for intravenous iron therapy, was considered as an absolute contraindication by up to 15.2% of all respondents. Anemia not caused by iron deficiency and iron overload, which are clear contraindications to intravenous iron therapy, were indicated as such by only 66% and 80% of all respondents respectively. Hypersensitivity for intravenous iron is the most dangerous contraindication and acute hypersensitivity reactions during infusion are very rare but can be life-threatening. A review by Rampton et al. provides recommendations about their management and prevention.²⁹ Importantly, if intravenous iron is to be given to individuals with any of the risk factors for acute hypersensitivity reactions (previous reaction to an iron infusion, a fast iron infusion rate, multiple drug allergies, severe atopy, systemic inflammatory diseases), an extremely slow infusion rate and meticulous observation is recommended. Finally, and notwithstanding the observed knowledge gap on PBM issues, possible long-term and potential hazardous effects of iron therapy in colorectal cancer patients are still unclear. Therefore, the long-term effects of iron therapy are not discussed in regard to the most optimal preoperative blood management strategy. Uncertainty on the potential role of iron in tumor progression arises from epidemiological and non-clinical studies, showing iron's role in all aspects of cancer development and cancer growth.²²⁻²⁶ Despite the fact that the conditions in these epidemiological and non-clinical studies often not reflect the clinical situation in anemic patients and often use excessive iron doses iron-replete animals, we believe well-designed clinical studies are required to exclude the potential long-term hazardous effect of iron therapy in cancer patients.

The increasing awareness to integrate PBM within routine surgical care, has resulted in numerous completed and ongoing trials studying the optimal blood management strategy in all types of surgery.^{11, 13, 27, 28} With regard to colorectal cancer, a pragmatic approach to the management of perioperative anemia is presented by Munoz et al.¹⁵ In this review, the use of PBM is strongly advocated to minimize or eliminate the use of allogeneic blood transfusion. Regarding the treatment of perioperative anemia, the use of oral iron is clearly dissuaded as it is poorly tolerated with low adherence based on published evidence, while the use of intravenous iron is strongly advised as it is safe and effective, but also frequently avoided due to misinformation and misinterpretation concerning the incidence and clinical nature of minor infusion reactions. In addition to this review and regarding the efficacy of intravenous iron therapy, a study by Keeler et al.¹² showed that intravenous iron is more effective in increasing hemoglobin level compared to oral iron, but did not observe a relevant

difference in the administration of red blood cell transfusions. However, in this trial the sample size was small and only primary outcomes in terms of increasing hemoglobin level and the use of red blood cell transfusions were reported, stressing the need for larger trials with a focus on functional performance and quality of life.¹¹ The results of such trials should provide more evidence surrounding the effectiveness of the management of preoperative anemia, and should contribute to successful implementation of PBM protocols, specifically in colorectal cancer patients.

Strengths and limitations

The key strength of our study is the availability of responses from gastroenterologists, surgeons and anesthesiologists. This enables comparison between different medical disciplines within and between hospitals. Our data sets allows assessing the knowledge of the different types of physicians and assessing the consensus in the management of preoperative anemia. In addition, in all hospitals except two, at least one physician responded to the survey. While the availability of responses from gastroenterologists, surgeons and anesthesiologists is a key strength of our study, it also appeared to be a limitation. Due to the high variety in responses, it was extremely difficult to determine the actual preoperative blood management strategy per hospital. An additional limitation of our study is that it is a national survey, hampering generalization of our results to an international setting. However, the Netherlands are known to be a pioneer in the implementation of PBM, using PBM strategies for more than two decades, especially for major orthopedic surgery.¹⁰ Therefore in other countries, physicians' knowledge of blood management issues and implementation of PBM in colorectal cancer care will presumably not be superior to the Dutch setting.

Conclusion

The present study shows a distinct variability in preoperative blood management practices in colorectal cancer care. Strikingly, this variability which was not only seen among, but also within Dutch hospitals, was demonstrated by variable responses from gastroenterologists, surgeons and anesthesiologists from the same institution. As a result, the present study clearly demonstrates the lack of consensus on PBM among gastroenterologists, surgeons and anesthesiologists, resulting in a suboptimal preoperative blood management strategy. For a more effective and uniform implementation of PBM, much progress could be made on education as the present study clearly

demonstrates a significant information deficit among physicians dealing with PBM issues. In addition, results of clinical trials providing evidence surrounding the effectiveness of treatment of preoperative anemia should contribute to more evidence-based guidelines. Finally, appointing key leaders for PBM project management should contribute to improved communication and cooperation, resulting in a more clear division in responsibilities among treating physicians.

Figure 1. Objective treatment preoperative anemia

Figure 2. Respondents opinions on contraindications for intravenous iron

Table 1. Characteristics/distribution respondents

	<i>n</i>	%
<i>Responses per specialism</i>		
Surgeons (177 invited in total)	95	53.7
Gastroenterologists (75 invited in total)	49	65.3
Anesthesiologists (75 invited in total)	48	64.0
<i>Responses per hospital (75 in total)</i>		
Surgeon(s)	8	10.7
Gastroenterologist	4	5.3
Anesthesiologist	9	12.0
Surgeon(s) + gastroenterologist	14	18.7
Surgeon(s) + anesthesiologist	12	16.0
Gastroenterologist + anesthesiologist	5	6.7
Surgeon(s) + gastroenterologist + anesthesiologist	21	28.0
No response	2	2.7

Table 2. Current practices for preoperative blood management in all centers (n=75), according to respondents

	n	%
<i>Iron parameters measured during screening colorectal cancer</i>		
Answered by: gastroenterologists and surgeons		
Yes	29	38.7
No	35	46.7
Unknown/missing	11	14.7
<i>Treatment of anemia first started by</i>		
Answered by: gastroenterologists, surgeons and anesthesiologists		
Gastroenterologist	11	14.7
Surgeon	15	20.0
Colon care nurse	4	5.3
Hematologist/internist	2	2.7
Anesthesiologist	2	2.7
Unclear/ambiguous policy	37	49.3
No treatment	1	1.3
Unknown/missing	3	4.0
<i>Iron parameters measured at preoperative assessment anesthesiology</i>		
Answered by: anesthesiologists		
Yes	8	10.7
No	37	49.3
Unknown/missing	30	40.0
<i>Treatment of anemia by anesthesiologists, regardless of previous treatment</i>		
Answered by: anesthesiologists		
Yes	10	13.3
No	34	45.3
Unknown/missing	31	41.3

Table 3. Decision making in treatment preoperative anemia

	Gastroenterologists, n (%)	Surgeons, n (%)	Anesthesiologists, n (%)	Total, n (%)
<i>A. Variables considered in decision making treatment preoperative anemia</i>				
Age of patient	16 (76.2)	12 (66.7)	3 (30)	31 (63.3)
Presence iron deficiency	19 (90.5)	13 (72.2)	5 (50)	37 (75.5)
Presence clinical symptoms anemia	20 (95.2)	14 (77.8)	8 (80)	42 (85.7)
Presence comorbidities	18 (85.7)	15 (83.3)	8 (80)	41 (83.7)
Severity of anemia	21 (100)	17 (94.4)	10 (100)	48 (98)
<i>B. Type of treatment (oral or intravenous iron) is dependent on type of iron deficiency (absolute versus functional iron deficiency)</i>				
Yes	3 (30)	4 (66.7)	1 (50)	8 (44.4)
No	7 (70)	2 (33.3)	1 (50)	10 (55.6)
<i>C. First choice of treatment in case of an absolute iron deficiency anemia</i>				
Oral iron	0 (0)	2 (50)	0 (0)	2 (28.6)
Intravenous iron	3 (100)	2 (50)	0 (0)	5 (71.4)
<i>D. First choice of treatment in case of a functional iron deficiency anemia</i>				
Oral iron	1 (33.3)	2 (66.7)	0 (0)	3 (50)
Intravenous iron	2 (66.7)	1 (33.3)	0 (0)	3 (50)

1. Fowler AJ, Ahmad T, Phull MK, et al. Meta-analysis of the association between preoperative anaemia and mortality after surgery. *Br J Surg*. 2015 Oct;102(11):1314-1324. PubMed PMID: 26349842.
2. Wilson MJ, van Haaren M, Harlaar JJ, et al. Long-term prognostic value of preoperative anemia in patients with colorectal cancer: A systematic review and meta-analysis. *Surg Oncol*. 2017 Mar;26(1):96-104. PubMed PMID: 28317592.
3. Ludwig H, Muldur E, Endler G, et al. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. *Ann Oncol*. 2013 Jul;24(7):1886-1892. PubMed PMID: 23567147.
4. Wilson MJ, Dekker JWT, Harlaar JJ, et al. The role of preoperative iron deficiency in colorectal cancer patients: prevalence and treatment. *Int J Colorectal Dis*. 2017 Sep 09. PubMed PMID: 28889320.
5. Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. *Ann Surg*. 2012 Aug;256(2):235-244. PubMed PMID: 22791100.
6. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. *Cochrane Database Syst Rev*. 2006 (1):CD005033. PubMed PMID: 16437512.
7. Busch OR, Hop WC, Hoyneck van Papendrecht MA, et al. Blood transfusions and prognosis in colorectal cancer. *N Engl J Med*. 1993 May 13;328(19):1372-1376. PubMed PMID: 8292113.
8. Halabi WJ, Jafari MD, Nguyen VQ, et al. Blood transfusions in colorectal cancer surgery: incidence, outcomes, and predictive factors: an American College of Surgeons National Surgical Quality Improvement Program analysis. *Am J Surg*. 2013 Dec;206(6):1024-1032; discussion 1032-1023. PubMed PMID: 24296103.
9. Harlaar JJ, Gosselink MP, Hop WC, et al. Blood transfusions and prognosis in colorectal cancer: long-term results of a randomized controlled trial. *Ann Surg*. 2012 Nov;256(5):681-686; discussion 686-687. PubMed PMID: 23095610.
10. Shander A, Van Aken H, Colomina MJ, et al. Patient blood management in Europe. *Br J Anaesth*. 2012 Jul;109(1):55-68. PubMed PMID: 22628393.
11. Borstlap WA, Buskens CJ, Tytgat KM, et al. Multicentre randomized controlled trial comparing ferric(III)carboxymaltose infusion with oral iron supplementation in the treatment of preoperative anaemia in colorectal cancer patients. *BMC Surg*. 2015;15:78. PubMed PMID: 26123286.
12. Keeler BD, Simpson JA, Ng O, et al. Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer. *Br J Surg*. 2017 Jan 16. PubMed PMID: 28092401.
13. Richards T, Clevenger B, Keidan J, et al. PREVENTT: preoperative intravenous iron to treat anaemia in major surgery: study protocol for a randomised controlled trial. *Trials*. 2015;16:254. PubMed PMID: 26041028.
14. Van der Linden P, Hardy JF. Implementation of patient blood management remains extremely variable in Europe and Canada: the NATA benchmark project: An observational study. *Eur J Anaesthesiol*. 2016 Dec;33(12):913-921. PubMed PMID: 27487910.
15. Munoz M, Gomez-Ramirez S, Martin-Montanez E, et al. Perioperative anemia management in colorectal cancer patients: a pragmatic approach. *World J Gastroenterol*. 2014 Feb 28;20(8):1972-1985. PubMed PMID: 24587673.

16. Sanquin. Blood Transfusion Guideline <https://www.sanquin.nl/repository/documenten/en/prod-en-dienst/287294/blood-transfusion-guideline.pdf>. 2014.
17. Fischer DP, Zacharowski KD, Muller MM, et al. Patient blood management implementation strategies and their effect on physicians' risk perception, clinical knowledge and perioperative practice - the frankfurt experience. *Transfus Med Hemother*. 2015 Mar;42(2):91-97. PubMed PMID: 26019704.
18. Mbanya D. Barriers and enablers to introducing comprehensive patient blood management in the hospital. *Biologicals*. 2012 May;40(3):205-208. PubMed PMID: 22316645.
19. Meybohm P, Froessler B, Goodnough LT, et al. "Simplified International Recommendations for the Implementation of Patient Blood Management" (SIR4PBM). *Perioper Med (Lond)*. 2017;6:5. PubMed PMID: 28331607.
20. Munoz M, Gomez-Ramirez S, Kozek-Langenecker S, et al. 'Fit to fly': overcoming barriers to preoperative haemoglobin optimization in surgical patients. *Br J Anaesth*. 2015 Jul;115(1):15-24. PubMed PMID: 26089443.
21. Vamvakas EC. Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice. *Transfusion*. 2013 Apr;53(4):888-901. PubMed PMID: 22882177.
22. Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer risk--a systematic review and meta-analysis of the epidemiological evidence. *Cancer Epidemiol Biomarkers Prev*. 2014 Jan;23(1):12-31. PubMed PMID: 24243555.
23. Ilsley JN, Belinsky GS, Guda K, et al. Dietary iron promotes azoxymethane-induced colon tumors in mice. *Nutr Cancer*. 2004;49(2):162-169. PubMed PMID: 15489209.
24. Stevens RG, Jones DY, Micozzi MS, et al. Body iron stores and the risk of cancer. *N Engl J Med*. 1988 Oct 20;319(16):1047-1052. PubMed PMID: 3173433.
25. Torti SV, Torti FM. Iron and cancer: more ore to be mined. *Nat Rev Cancer*. 2013 May;13(5):342-355. PubMed PMID: 23594855.
26. Zhang C, Zhang F. Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. *Protein Cell*. 2015 Feb;6(2):88-100. PubMed PMID: 25476483.
27. Froessler B, Palm P, Weber I, et al. The Important Role for Intravenous Iron in Perioperative Patient Blood Management in Major Abdominal Surgery: A Randomized Controlled Trial. *Ann Surg*. 2016 Jan 27. PubMed PMID: 26817624.
28. Investigators I, Litton E, Baker S, et al. Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial : A randomized trial of IV iron in critical illness. *Intensive Care Med*. 2016 Nov;42(11):1715-1722. PubMed PMID: 27686346.
29. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. *Haematologica*. 2014 Nov;99(11):1671-1676. PubMed PMID: 25420283.